The branded and generic drugmaker's Q2 EPS rose 12% to $1.42 vs. views for $1.15. In June, Endo Health Solutions (ENDP) said it planned to cut 15% of staff, about 700 jobs, and would consider strategic options for its HealthTronics urology business and branded drug development platform. Revenue slid 2.4% to $766.5 mil, topping predictions of $721 mil. Endo expects EPS of $4.25-$4.55 in '13, beating analyst forecasts of $4.33. Shares fell 3%.